Literature DB >> 2112981

Major histocompatibility complex class I and unique antigen expression by murine tumors that escaped from CD8+ T-cell-dependent surveillance.

P L Ward1, H K Koeppen, T Hurteau, D A Rowley, H Schreiber.   

Abstract

The rejection of murine UV-induced skin cancers by normal mice is a striking example of powerful immune surveillance of the normal host against malignant cells. In this study, we show that UV-induced regressor tumors regularly grew progressively and killed mice that were depleted of CD8+ T-cells. Depletion of CD4+ T-cells had no effect, suggesting that CD8+ but not CD4+ T-cells were required for this immune surveillance. To determine whether change in major histocompatibility complex (MHC) class I expression was a frequent event that caused low immunogenicity of tumors or facilitated escape from immune destruction, recently isolated murine tumors of varying degrees of immunogenicity, including highly immunogenic UV-induced regressor, less immunogenic UV-induced progressor, and poorly immunogenic spontaneous progressor tumors, were compared. There was no correlation between the ability of a tumor to grow progressively in a normal immunocompetent host and the level of constitutive class I expression or the level of expression induced in vitro by gamma interferon. (Only 1 of more than 20 progressor tumors analyzed showed complete loss of a MHC class I molecule.) Some progressor variants showed loss of a unique tumor-specific cytotoxic T-lymphocyte-defined antigen, consistent with earlier evidence of antigen loss providing a mechanism for tumor escape. However, most of the host-selected progressor variants retained both MHC class I antigens and the unique tumor antigens that we could detect with cytotoxic T-lymphocyte clones, suggesting that mechanisms other than loss of MHC class I or of the unique target antigen may be involved in escape of some tumors from a highly effective CD8-dependent host surveillance.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2112981

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  26 in total

1.  Recurrence of melanoma following T cell treatment: continued antigen expression in a tumor that evades T cell recruitment.

Authors:  Trudy Straetemans; Cor Berrevoets; Miriam Coccoris; Elike Treffers-Westerlaken; Rebecca Wijers; David K Cole; Valerie Dardalhon; Andrew K Sewell; Naomi Taylor; Jaap Verweij; Reno Debets
Journal:  Mol Ther       Date:  2014-11-03       Impact factor: 11.454

Review 2.  Targeting stroma to treat cancers.

Authors:  Boris Engels; Donald A Rowley; Hans Schreiber
Journal:  Semin Cancer Biol       Date:  2011-12-24       Impact factor: 15.707

3.  Ribosomal versus non-ribosomal cellular antigens: factors determining efficiency of indirect presentation to CD4+ T cells.

Authors:  Mary Philip; Andrea Schietinger; Hans Schreiber
Journal:  Immunology       Date:  2010-03-16       Impact factor: 7.397

Review 4.  Targeting cancer-specific mutations by T cell receptor gene therapy.

Authors:  Thomas Blankenstein; Matthias Leisegang; Wolfgang Uckert; Hans Schreiber
Journal:  Curr Opin Immunol       Date:  2015-02-27       Impact factor: 7.486

5.  Delivery of foreign cytotoxic T lymphocyte epitopes to tumor tissues for effective antitumor immunotherapy against pre-established solid tumors in mice.

Authors:  Herbert W Kavunja; Shuyao Lang; Suttipun Sungsuwan; Zhaojun Yin; Xuefei Huang
Journal:  Cancer Immunol Immunother       Date:  2016-12-23       Impact factor: 6.968

Review 6.  T cells in tumor microenvironment.

Authors:  Yağmur Kiraz; Yusuf Baran; Ayten Nalbant
Journal:  Tumour Biol       Date:  2015-10-18

7.  Predictors of response and resistance to checkpoint inhibitors in solid tumors.

Authors:  Sanjana V Rao; Amy E Moran; Julie N Graff
Journal:  Ann Transl Med       Date:  2017-12

Review 8.  Immune surveillance of tumors.

Authors:  Jeremy B Swann; Mark J Smyth
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

9.  Immunological characterization of tumor-rejection antigens on ultraviolet-light-induced tumors originating in the CB6F1 mouse.

Authors:  T Kitajima; M Iwashiro; K Kuribayashi; S Imamura
Journal:  Cancer Immunol Immunother       Date:  1994-06       Impact factor: 6.968

10.  Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas.

Authors:  Claudia Curcio; Emma Di Carlo; Raphael Clynes; Mark J Smyth; Katia Boggio; Elena Quaglino; Michela Spadaro; Mario P Colombo; Augusto Amici; Pier-Luigi Lollini; Piero Musiani; Guido Forni
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.